Company profile / SLS

SELLAS Life Sciences Group

Clinaptis stanceCautious
ConvictionMedium
Ticker
SLS
Exchange
NASDAQ
Coverage
Standard profile
Updated
Nov 19, 2026
Oncology / Hematology

Clinical-stage acute myeloid leukemia (AML) company with 14 employees. Galinpepimut-S (GPS), a WT1 peptide vaccine, won its Phase 3 REGAL trial as maintenance after a second or later remission: median overall survival of 24.0 months against 14.7 on best available therapy (HR 0.59, p=0.035; 126 patients, 80 deaths). Tambiciclib (SLS009), a CDK9 inhibitor, is in Phase 2 in relapsed and newly diagnosed AML. SELLAS priced a $150M offering at $13.00 on 18 November 2026.

01 / Clinaptis view

The current read

REGAL is a real survival win, but the price outruns the patients. We back-calculate a 95% confidence interval of about 0.36–0.96 around the 0.59 hazard ratio, close to no effect at the upper end, and SELLAS has not disclosed the analysis set, the survival curves or the transplant counts.

  1. On our numbers SELLAS is worth $5.48 a share on self-launch economics and about $9.20 to an acquirer, against a $17.95 close on 18 November and the $13.00 offering price. At our base course, $17.95 needs ~1,540 US patients treated a year on acquirer economics, more than twice our ~640 base case. Only a longer, pricier course (~1,110 patients) fits under our ~1,280 eligible-patient ceiling, and only at ~87% of eligible patients. Acquirer value cleared $17.95 in 0.3% of 100,000 simulated scenarios.
  2. We are cautious, not short. Short interest was ~28% before the readout, two SLS009 readouts land within weeks, and a buyer could use more generous inputs than ours. This is research, not a call on SLS.
02 / Consensus gap

Where the market may differ

The market is pricing different inputs than we are. At $17.95 SELLAS carried a ~$3.66B market cap before the offering and an enterprise value ~3x Syndax's, which already sells two approved drugs. Our values of $5.48 and $9.20 a share sit 69% and 49% below the close.

  1. The gap is mostly commercial. SELLAS's 10-K sizes ~3,750 eligible US patients a year; we get ~960 on an evidence-adjusted basis (~1,115 in our base funnel, ~1,280 with later remissions). The one approved AML maintenance drug, oral azacitidine, implies ~420 US patient-years on drug in its third full year.
  2. The favorable case that reaches $19.87 needs a 65% share, 90% approval odds, $375k for the first year and two years on therapy. We think the patient count, the share and the approval odds are each aggressive for a single open-label trial.
Coverage state
Standard profile
What the review turns on
Key variable

How many of the ~1,280 eligible US patients a year a buyer could put on GPS, for how long and at what price (we model ~640 treated; $17.95 needs ~1,540 on acquirer economics)

Next catalyst

Offering close · 20 Nov 2026; SLS009 relapsed-AML data at ASH · 12–15 Dec 2026; preliminary frontline SLS009 data · Q4 2026

03 / Pipeline

Key programs

3 assets · 4 programs

AssetIndicationStageNext event
Galinpepimut-S (GPS)
AML maintenance in second or later remission
Phase 3 completed
Full REGAL data (confidence interval, analysis set, survival curves, transplant counts); FDA meeting on SELLAS's accelerated filing strategy; BLA targeted for 1H 2027
Tambiciclib (SLS009)
Relapsed or refractory AML
Phase 2
ASH presentation, 12–15 Dec 2026
Newly diagnosed high-risk AML
Phase 2
Preliminary data guided for Q4 2026; cohorts and follow-up undisclosed
Galinpepimut-S (GPS)
Solid tumors (mesothelioma, ovarian)
Early trials completed
No active study; we give an 8% chance of reaching market
04 / Connected research

Published on SLS

View full archive
  1. 01

    Cautious on SELLAS (SLS): Galinpepimut-S Improved Survival in AML. But Price Outruns the Patients.

    How much is REGAL’s survival benefit worth? We start with SELLAS’s ~$3.7B valuation and give SLS009 and the rest of the pipeline some credit. That leaves GPS. About 1,280 US patients could start GPS each year. How many would need to start, how long would they stay on it, and what price would make the numbers work for a buyer?

    Read